Skip to main content
Journal cover image

Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation

Publication ,  Journal Article
Fock, KM; Wagner, A; Ahad, MA; Ahmed, DS; Ahmed, F; Ahmed, MM; Ali, MS; Bhuiyan, MR; Chowdhury, D; Hasan, M; Ishaqe, SM; Kabir, A; Khan, MR ...
Published in: Journal of Gastroenterology and Hepatology (Australia)
August 1, 2007

Background and Aim: The 5-HT4receptor agonist tegaserod (6 mg b.i.d.) provides significantly better overall multiple symptom relief compared with placebo in patients with irritable bowel syndrome with constipation (IBS-C). The clinical benefit and safety of tegaserod in IBS-C patients has been demonstrated worldwide in several studies. The aim of this study was to obtain further safety and tolerability data in patients with IBS in the Asia-Pacific region, and to assess patients' satisfaction and compliance with treatment and willingness to re-use tegaserod in a post-marketing setting. Methods: A multicenter, single-arm, open-label trial was conducted at 869 outpatient centers in 10 countries. Men and women with IBS, whose predominant bowel symptom was not diarrhea (non-D-IBS), received tegaserod for 4-12 weeks. Safety and tolerability were assessed by recording adverse events (AE). Patients were questioned about compliance, satisfaction with treatment and willingness to use tegaserod in future. Results: Data were available from 14 537 patients (18% men, 82% women). Four percent of patients reported at least one AE. The most common AE were diarrhea (2%) and abdominal pain (1%), and most treatment-related AE occurred in the first week of treatment. Serious AE (SAE) were observed in eight patients, and no deaths were reported. Most patients (79%) reported to be satisfied or very satisfied with treatment, and 76% stated they would use tegaserod in the future. Compliance was 97%. Conclusions: Tegaserod has a favorable safety and tolerability profile for treating non-D-IBS and IBS-C in men and women in the Asia-Pacific region. Satisfaction with tegaserod treatment can be expected in the majority of patients. © 2007 The Authors.

Duke Scholars

Published In

Journal of Gastroenterology and Hepatology (Australia)

DOI

EISSN

1440-1746

ISSN

0815-9319

Publication Date

August 1, 2007

Volume

22

Issue

8

Start / End Page

1190 / 1198

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fock, K. M., Wagner, A., Ahad, M. A., Ahmed, D. S., Ahmed, F., Ahmed, M. M., … Li, J. S. (2007). Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. Journal of Gastroenterology and Hepatology (Australia), 22(8), 1190–1198. https://doi.org/10.1111/j.1440-1746.2007.04955.x
Fock, K. M., A. Wagner, M. A. Ahad, D. S. Ahmed, F. Ahmed, M. M. Ahmed, M. S. Ali, et al. “Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.” Journal of Gastroenterology and Hepatology (Australia) 22, no. 8 (August 1, 2007): 1190–98. https://doi.org/10.1111/j.1440-1746.2007.04955.x.
Fock KM, Wagner A, Ahad MA, Ahmed DS, Ahmed F, Ahmed MM, et al. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. Journal of Gastroenterology and Hepatology (Australia). 2007 Aug 1;22(8):1190–8.
Fock, K. M., et al. “Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.” Journal of Gastroenterology and Hepatology (Australia), vol. 22, no. 8, Aug. 2007, pp. 1190–98. Scopus, doi:10.1111/j.1440-1746.2007.04955.x.
Fock KM, Wagner A, Ahad MA, Ahmed DS, Ahmed F, Ahmed MM, Ali MS, Bhuiyan MR, Chowdhury D, Hasan M, Ishaqe SM, Kabir A, Khan MR, Masud H, Masud MA, Rab Sarkar MA, Rahim Mia MA, Rahman MH, Raihan ASMA, Rowsan AHM, Roy PK, Saha SK, Bai WY, Cai JT, Cao B, Chang XM, Chen JF, Chen JX, Chen JY, Chen LD, Chen LJ, Chen MX, Chen WC, Chen WX, Chen XM, Chen Y, Chen YL, Chen YS, Cheng JX, Cui XY, Deng MM, Ding YJ, Dong JD, Dong L, Dong SX, Du GP, Duan LP, Fan DM, Fan ZJ, Fang DC, Feng H, Feng K, Feng YK, Feng ZT, Fu BY, Fu J, Gan AH, Gao XY, Gao XZ, Gong FL, Gong FY, Gong L, Gu GM, Gu XH, Guo HX, Guo XZ, Guo YM, Hai LQM, Han RG, Han SX, Han Z, Hong Y, Hou JR, Hou XH, Hu Y, Hu ZK, Hua DW, Huang GM, Huang H, Huang JF, Huang KM, Huang LY, Huang SP, Huang XF, Huang YM, Huang ZJ, Huo LJ, Ji F, Ji ZZ, Jia LP, Jian FH, Jiang YB, Kan ZC, Li B, Li BJ, Li DG, Li FK, Li FR, Li JJ, Li JS. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. Journal of Gastroenterology and Hepatology (Australia). 2007 Aug 1;22(8):1190–1198.
Journal cover image

Published In

Journal of Gastroenterology and Hepatology (Australia)

DOI

EISSN

1440-1746

ISSN

0815-9319

Publication Date

August 1, 2007

Volume

22

Issue

8

Start / End Page

1190 / 1198

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1103 Clinical Sciences